查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362868

呼吸道融合细胞病毒诊断市场规模、份额和趋势分析报告：2023-2030 年按产品、最终用途、地区和细分市场分類的趋势

Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10个工作天内

价格

呼吸道融合细胞病毒诊断市场成长与趋势：

Grand View Research, Inc. 的一项新研究显示，到 2030 年，全球呼吸道融合细胞病毒诊断市场预计将达到 19.473 亿美元，2023 年至 2030 年年复合成长率预计为 9.7%。

罹患呼吸道疾病（包括 RSV感染疾病）的新生儿人数不断增加，以及医疗保健提供者对新生儿诊断的支持倡议预计将成为 RSV 诊断市场的关键影响促进因素。

根据世界卫生组织统计，2014年美国有超过15万名儿童（5岁以下）因RSV感染疾病住院，约1.4万名老年患者死亡。预计这将推动预测期内对这些疾病的检测需求。

此外，截至2014年，全球出生率为每1,000人18.7个孩子，预计未来年度婴幼儿人口将大幅增加。根据统计，2014年估计约有1.342亿生产，这些生产由于容易感染疾病RSV并需要诊断，形成了庞大的市场基础。

2010 年，透过筛检拯救婴儿基金会 (SBTS) 与世界传染病解决方案 (WSAID) 合作发起了一项倡议，以促进新生儿感染疾病、代谢紊乱和听力损失筛检。

呼吸道融合细胞病毒诊断市场报告亮点

  • 基于色谱免疫检测技术的产品预计将成长最快，未来年度年复合成长率将超过10.0%，因为它们比分子诊断产品更具特异性。市售检测套组包括 Binax Now RSV、QuickLab RSV Test、Remel Xpect 和 RSV Respi-Strip。
  • 医院预计将主导 RSV 诊断市场，其次是居家医疗。预计到 2022 年，它们将占据超过 50.0% 的市场占有率。患者对居家医疗诊断设备的需求增加预计将在未来年度推动该领域的成长。
  • 预计到 2022 年，北美将占据市场主导地位，占据超过 41.5% 的销售份额。民众对启动和实施新生儿筛检的认识不断提高，以及世界卫生组织、泛美卫生组织和 WSAID 等政府机构的有利配合措施预计将推动成长。
  • 市场的主要企业包括 Alere Inc.、EMD Millipore、BD and Company、Ortho Clinical Diagnostics、Roche Diagnostics、Abbott Laboratories 和 Thermo Fisher Scientific Inc.。 Roche Diagnostics、Becton Dickinson and Company 和 Alere Inc. 等公司的 CLIA 批准和 RSV 检测的推出预计将在预测期内推动市场成长。

目录

第1章调查方法和范围

第2章执行摘要

第3章呼吸道融合细胞病毒(RSV) 诊断市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 呼吸道融合细胞病毒（RSV）诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章呼吸道融合细胞病毒（RSV）诊断市场：产品评估与趋势分析

  • 呼吸道融合细胞病毒(RSV) 诊断市场：重点
  • 呼吸道融合细胞病毒(RSV) 诊断市场：2022 年和 2030 年趋势和市场占有率分析
  • 直接萤光抗体（DFA）法
  • 快速抗原诊断测试 (RADT)
  • 分子诊断
  • 层析免疫分析法
  • 影像诊断
  • 凝胶微滴
  • 流式细胞仪
  • 其他的

第5章呼吸道融合细胞病毒（RSV）诊断市场：最终用途估计与趋势分析

  • 呼吸道融合细胞病毒(RSV) 诊断市场：重点
  • 呼吸道融合细胞病毒(RSV) 诊断市场：2022 年和 2030 年趋势和市场占有率分析
  • 医院
  • 实验室
  • 诊所
  • 居家护理

第6章呼吸道融合细胞病毒（RSV）诊断市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的呼吸道融合细胞病毒(RSV) 诊断市场：主要市场点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Becton, Dickinson and Company
    • Novartis AG
    • Abbott
    • Ortho Clinical Diagnostics
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd
    • BIOMERIEUX
    • DiaSorin SpA
    • Merck KGaA
    • Quidel Corporation
    • Coris BioConcept
    • Quest Diagnostics
    • Siemens Healthcare SA
Product Code: 978-1-68038-680-6

Respiratory Syncytial Virus Diagnostics Market Growth & Trends:

The global respiratory syncytial virus diagnostics market is expected to reach USD 1947.3 million by 2030, growing at an estimated CAGR of 9.7% from 2023 to 2030, according to a new study by Grand View Research, Inc.. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Respiratory Syncytial Virus Diagnostics Market Report Highlights:

  • Chromatographic immunoassay technology based products are expected to witness the fastest growth at a CAGR above 10.0% over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
  • Hospitals are predicted to dominate the RSV diagnostics market followed by home care. Together, they are expected to contribute over 50.0% of the market share in 2022. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
  • North America is anticipated to dominate the market and contribute a revenue share of over 41.5% by 2022. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
  • Key players of the market include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. End-use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Respiratory Syncytial Virus (RSV) Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Respiratory Syncytial Virus (RSV) Diagnostic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Respiratory Syncytial Virus (RSV) Diagnostic Market: Product Estimates & Trend Analysis

  • 4.1. Respiratory Syncytial Virus (RSV) Diagnostic Market: Key Takeaways
  • 4.2. Respiratory Syncytial Virus (RSV) Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Direct Fluorescent Antibody (DFA) Method
    • 4.3.1. Direct fluorescent antibody (DFA) Method estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Rapid Antigen Diagnostic Test (RADT)
    • 4.4.1. Rapid Antigen Diagnostic Test (RADT) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Molecular Diagnostics
    • 4.5.1. Molecular diagnostic market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Chromatographic Immunoassay
    • 4.6.1. Chromatographic immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Diagnostic Imaging
    • 4.7.1. Diagnostic imaging Immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Gel Microdroplets
    • 4.8.1. Gel microdroplets imaging immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Flow Cytometry
    • 4.9.1. Flow cytometry imaging immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Respiratory Syncytial Virus (RSV) Diagnostic Market: End-use Estimates & Trend Analysis

  • 5.1. Respiratory Syncytial Virus (RSV) Diagnostic Market: Key Takeaways
  • 5.2. Respiratory Syncytial Virus (RSV) Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Laboratory
    • 5.4.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Clinics
    • 5.5.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Homecare
    • 5.6.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Respiratory Syncytial Virus (RSV) Diagnostic Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Respiratory Syncytial Virus (RSV) Diagnostic Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Becton, Dickinson and Company
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Novartis AG
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Abbott
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Ortho Clinical Diagnostics
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Thermo Fisher Scientific Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bio-Rad Laboratories, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F. Hoffmann-La Roche Ltd
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. BIOMERIEUX
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. DiaSorin S.p.A.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Merck KGaA
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Quidel Corporation
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Coris BioConcept
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Quest Diagnostics
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Siemens Healthcare S.A.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 10 Europe respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Europe respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 12 UK respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 13 UK respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Germany respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 15 Germany respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 17 France respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 19 Italy respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 21 Spain respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 23 Denmark respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 25 Sweden respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 27 Norway respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific respiratory syncytial virus diagnostic market, by region, (USD Million) 2018 - 2030
  • Table 31 Japan respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 32 Japan respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 China respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 34 China respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 36 India respiratory syncytial virus diagnostic market, by end-use, (USD Million) 2018 - 2030
  • Table 37 Australia respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 38 Australia respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Thailand respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 40 Thailand respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 42 South Korea respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 44 Latin America respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Latin America respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 47 Brazil respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 49 Mexico respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 51 Argentina respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa respiratory syncytial virus diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Africa respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 60 UAE respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait respiratory syncytial virus diagnostic market, by product, 2018 - 2030 (USD Million)
  • Table 62 Kuwait respiratory syncytial virus diagnostic market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Respiratory syncytial virus diagnostic: Market outlook
  • Fig. 9 Respiratory syncytial virus diagnostic: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Respiratory syncytial virus diagnostic market driver impact
  • Fig. 15 Respiratory syncytial virus diagnostic market restraint impact
  • Fig. 16 Respiratory syncytial virus diagnostic market strategic initiatives analysis
  • Fig. 17 Respiratory syncytial virus diagnostic market: Product movement analysis
  • Fig. 18 Respiratory syncytial virus diagnostic market: product outlook and key takeaways
  • Fig. 19 Direct fluorescent antibody (DFA) method market estimates and forecasts, 2018 - 2030
  • Fig. 20 Rapid antigen diagnostic test (RADT) market estimates and forecasts, 2018 - 2030
  • Fig. 21 Molecular diagnostic market estimates and forecasts, 2018 - 2030
  • Fig. 22 Chromatographic immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 23 Diagnostic imaging market estimates and forecasts, 2018 - 2030
  • Fig. 24 Gel microdroplets immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 25 Flow cytometry immunoassay market estimates and forecasts, 2018 - 2030
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030
  • Fig. 27 Respiratory syncytial virus diagnostic market: End-use movement analysis
  • Fig. 28 Respiratory syncytial virus diagnostic market: End-use outlook and key takeaways
  • Fig. 29 Hospital market estimates and forecasts, 2018 - 2030
  • Fig. 30 Laboratory market estimates and forecasts, 2018 - 2030
  • Fig. 31 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 32 Homecare market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global respiratory syncytial virus diagnostic market: Regional movement analysis
  • Fig. 34 Global respiratory syncytial virus diagnostic market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 41 France market estimates and forecasts, 2018 - 2030
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 44 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 45 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 46 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 49 China market estimates and forecasts, 2018 - 2030
  • Fig. 50 India market estimates and forecasts, 2018 - 2030
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 56 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030